Year: 2010
Type: editorial
Abstract: Nearly 30 years ago, the initial report of a child with thalassemia major who was treated successfully with allogeneic bone marrow transplantation (BMT) established the potential to cure this disorder using cellular therapy. The decades that followed witnessed the evolution from a therapy that was restricted initially to those who had a human leukocyte antigen–identical sibling donor and satisfied restrictive eligibility criteria to the current era, in which improved outcomes after unrelated and sibling donor transplantation among high-risk and good-risk recipients have converged.
Source: Molecular Therapy
DOI: 10.1038/mt.2010.184
Author: Mark C Walters
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2080645626